Introduction {#intro}
============

Results obtained from the Scandinavian arthroplasty registries ([@CIT0016], [@CIT0037], [@CIT0024]) on a nation-by-nation basis and studies from single centers worldwide ([@CIT0004], [@CIT0042], [@CIT0009], [@CIT0007], [@CIT0027]) have indicated that cemented total hip replacement is the treatment of choice for severe osteoarthritis in elderly patients. However, in a recent study based on data obtained from the Finnish Arthroplasty Register, cementless implants were found to have similar long-term survival rates as cemented implants in patients aged 55 years or more ([@CIT0029]). Several studies ([@CIT0002], [@CIT0005], [@CIT0020], [@CIT0025], [@CIT0026], [@CIT0032], [@CIT0034]) have shown that the survival rates of cementless stems have been satisfactory for all age groups, but cementless cups have a common problem of liner wear, osteolysis, and high incidence of revision in the medium-to-long term ([@CIT0003], [@CIT0023], [@CIT0017], [@CIT0010]).

We therefore separately analyzed the survival rates of the most common cementless designs performed for primary osteoarthritis in patients aged 55 years or older in Finland, and compared the risk of revision for each implant with that of the cemented implant reference group ([@CIT0030]). These analyses were carried out on population-based data obtained from the Finnish Arthroplasty Register for the period 1980 through 2005.

Patients and methods {#ss2}
====================

Since 1980, data on total hip replacements have been collected and archived in the Finnish Arthroplasty Register ([@CIT0033], [@CIT0037]). Healthcare authorities, institutions, and orthopedic units in Finland are obliged to provide the National Agency for Medicines with information that is essential for monitoring past and current trends for the efficacious use of materials, approaches, and designs used in orthopedics. The coverage in the Finnish Arthroplasty Register was initially analyzed for the period 1994--1995 by comparing its data with those of the discharge registers of participating hospitals; the Register covered 90% of all implantations performed ([@CIT0037]). Since 1995, the data in the register have been compared with those of hospital discharge registers every few years. Currently, 98% of implantations are recorded in the Finnish Arthroplasty Register (Peltola 2008).

Study population and inclusion criteria {#ss3}
---------------------------------------

During the study period (1980--2005), 101,720 primary total hip replacements were performed in Finland. Of these, 87,578 (86%) were performed on patients aged 55 years or older. Primary osteoarthritis was the indication in 71,146 (81%) of these operations; cementless total hip implants were used in 30,112 (42%).

Only designs used in more than 500 operations during the study period and designs with more than 20 hips at risk at 5 years were included in the current study. These criteria permitted the inclusion of 8 designs (10,310 replacements) ([Table 1](#T1){ref-type="table"}). The risk of revision for each design was compared with that for 9,549 cemented reference implants ([Table 2](#T2){ref-type="table"}). A 10-year survival rate exceeding 90% is commonly regarded as a good long-term outcome (National Institute of Clinical Excellance, NICE). The 3 best performing cemented designs in Finland ([@CIT0030]) fulfilled this criterion and were chosen as reference implants. These 3 cemented designs were the Exeter Universal stem combined with the All-poly cup (Stryker, Mahwah, NJ), the Müller Straight stem combined with the Müller Standard cup (Zimmer, Warsaw, IN), and the Lubinus SP II stem combined with the Lubinus IP cup (Waldemer Link, Hamburg, Germany). Survival analyses were performed for the whole study population and separately for each of 3 age cohorts: 55--64 years, 65--74 years, and 75 years and older. The data from subgroup analysis were massive and only the data with "any reason" as cause of revision are presented ([Table 7](#T7){ref-type="table"}).

###### 

Demographic data of the implants analyzed

  THR Brands            No.      Mean follow-up   Mean age   Women   (%) No. of hospitals   Period of implantation
  --------------------- -------- ---------------- ---------- ------- ---------------------- ------------------------
  Anatomic Mesh/HG-II   604      11.1             63         56      24                     1989--1997
  PCA Std/PCA Pegged    508      11.6             63         55      23                     1985--1995
  Bi-Metric/PFU         2,687    8.8              63         49      53                     1986--2001
  Bi-Metric/Mallory     637      8.7              67         60      11                     1989--2000
  Bi-Metric/Vision      2,055    3.4              65         48      47                     1998--2005
  ABG I/ABG I           565      9.1              65         55      25                     1992--1997
  ABG I/ABG II          1,765    5.9              66         51      36                     1996--2003
  ABG II/ABG II         1,489    2.5              67         55      31                     2000--2005
  Cemented reference    9,549    8.8              72         66      62                     1980--2005
  Together              19,859   7.6              68         59      77                     1980--2005

###### 

Material, surface, design features, and manufacturer of the implants. For abbreviations, see [Table 1](#T1){ref-type="table"}

  THR Brands           Material          Surface                                 Special design features                         Manufacturer
  -------------------- ----------------- --------------------------------------- ----------------------------------------------- -------------------
  *Stems*                                                                                                                        
   Bi-Metric           Titanium alloy    Proximally porous-coated                Straight, collarless                            Biomet
   Anatomic Mesh       Titanium alloy    Proximally porous-coated                Anatomic                                        Zimmer
   ABG I               Titanium alloy    Proximally grit-blasted and HA-coated   Anatomic                                        Stryker Howmedica
   ABG II              Titanium alloy    Proximally grit-blasted and HA-coated   Anatomic                                        Stryker Howmedica
   PCA Standard        CoCr alloy        Proximally porous-coated                Anatomic                                        Stryker Howmedica
   Exeter Universal    Stainless steel   Polished                                Straight, collarless, cemented                  Stryker Howmedica
   Müller Straight     CoCr alloy        Matt                                    Straight, small collar, fluted macrostructure   Zimmer
   Lubinus SP II       CoCr alloy        Matt                                    Anatomic, collar, modular                       Link
  *Cups*                                                                                                                         
   ABG I               Titanium alloy    Grit-blasted and HA-coated              Hemispherical, open screw-holes                 Stryker Howmedica
   ABG II              Titanium alloy    Grit-blasted and HA-coated              Hemispherical, screw-holes plugged              Stryker Howmedica
   Biomet Mallory      Titanium alloy    Porous-coated                           Hemispherical, open screw-holes, fins           Biomet
   Biomet Universal    Titanium alloy    Porous-coated                           Hemispherical, open screw-holes                 Biomet
   Biomet Vision       Titanium alloy    Porous-coated                           Hemispherical, screw-holes plugged              Biomet
   Harris-Galante II   Titanium alloy    Porous-coated                           Hemispherical, open screw-holes                 Zimmer
   PCA Pegged          Cobalt-chromium   Porous-coated                           Hemispherical, open screw-holes                 Stryker Howmedica
   Exeter All-poly     Polyethylene      --                                      Cemented                                        Stryker Howmedica
   Müller Std          Polyethylene      --                                      Cemented                                        Zimmer
   Lubinus IP          Polyethylene      --                                      Groove design                                   Link

Revisions were linked to the primary operation by using the patient\'s personal identification number; these numbers are assigned to every resident of Finland. Numbers and indications for revision were recorded ([Table 3](#T3){ref-type="table"}).

###### 

Reasons for revision of the 8 most common cementless brands and the cemented reference designs. Percentage in parentheses. For prosthesis types, see [Table 1](#T1){ref-type="table"}

  A                     B        C          D          E          F        G          H         I        J         K          L
  --------------------- -------- ---------- ---------- ---------- -------- ---------- --------- -------- --------- ---------- -------
  Anatomic Mesh/HG-II   604      17 (15)    23 (20)    17 (15)    0 (0)    4 (4)      7 (6)     4 (4)    2 (2)     39 (35)    113
  PCA Std/PCA Pegged    508      19 (14)    81 (60)    19 (14)    2 (2)    1 (1)      2 (2)     0 (0)    1 (1)     10 (7)     135
  Bi-Metric/PFU         2,687    26 (8)     67 (19)    10 (3)     9 (3)    57 (17)    14 (4)    16 (5)   15 (4)    131 (38)   345
  Bi-Metric/Mallory     637      5 (8)      11 (17)    3 (5)      1 (2)    12 (19)    3 (5)     5 (8)    3 (5)     21 (33)    64
  Bi-Metric/Vision      2,055    11 (16)    1 (1)      6 (9)      8 (12)   28 (41)    5 (7)     0 (0)    4 (6)     6 (9)      69
  ABG I/ABG I           565      10 (9)     27 (26)    3 (3)      1 (1)    6 (6)      3 (3)     3 (3)    6 (6)     47 (44)    106
  ABG I/ABG II          1,765    1 (2)      6 (10)     2 (3)      5 (8)    13 (21)    10 (16)   1 (2)    10 (16)   15 (24)    63
  ABG II/ABG II         1,489    2 (4)      1 (2)      3 (6)      3 (6)    10 (20)    7 (14)    4 (8)    19 (37)   2 (4)      51
  Cemented reference    9,549    227 (28)   142 (18)   253 (32)   38 (5)   73 (9)     20 (3)    5 (1)    24 (3)    16 (2)     798
  Together              19,859   318 (18)   359 (21)   316 (18)   67 (4)   204 (12)   71 (4)    38 (2)   84 (5)    287 (17)   1,744

Statistics {#ss4}
----------

The endpoint for survival was defined as revision when any component (including femoral head and liner) or the whole implant was removed or exchanged. Survival rates for stems and cups were analyzed separately with revision for aseptic loosening being used as the endpoint. When survival analyses were conducted for total hip replacements (cup + stem combinations), both revision for any reason and revision for aseptic loosening served as discrete endpoints. Kaplan-Meier survival analysis was used to calculate the survival probabilities of implants at 7, 10, and 15 years. The survival rate of any respective implant was determined only when there were at least 20 hips at risk at the follow-up point ([@CIT0013]). Patients who had died or emigrated from Finland during the follow-up period were censored at that point. Survival data obtained by Kaplan-Meier analysis were compared by the log-rank test. The Cox multiple regression model was used to study differences between implants and to adjust for potential confounding factors.

Both Kaplan-Meier and Cox regression are methods based on assumptions of independent observations. However, bilateral observations cannot be regarded as being independent ([@CIT0039], [@CIT0006]). Violation of this independence assumption may have an effect on the validity of the results. To avoid this violation, the data analysis could be performed by allowing inclusion of correlated observations, e.g. including only one prosthesis per patient or by including a shared frailty variable in the Cox regression. In the current study, however, bilateral observations were included in the dataset analyzed. It has been found that the effect of neglecting bilateral prostheses is minute ([@CIT0015], [@CIT0039], [@CIT0022]).

Risk of revision ratios of stems, cups, and total hip replacements (cup + stem combinations) were analyzed. Adjustments were made for age and sex. The 3 best performing cemented designs in Finland were chosen as reference implants ([@CIT0030]). The survival data of these cemented designs were combined to form a single reference group. Cox regression analyses provided survival probabilities and adjusted risk ratios for revision. Estimates derived from the Cox analyses were used to construct adjusted survival curves at mean values of the risk factors. The proportional hazards assumption of the Cox model (meaning that the relative difference between revision rates should be constant over time since the primary operation) was not reached in some analyses performed. Thus, adjusted risk ratios were also established within time intervals (0--7 years, 7 years after the primary operation). The Wald test was used to calculate the p-values for data obtained from the Cox multiple regression analyses. A difference between groups was considered to be statistically significant if the p-value was less than 0.05 in a two-tailed test.

Results {#ss5}
=======

Survival of stems -- aseptic loosening {#ss6}
--------------------------------------

When all patients aged 55 years or more were analyzed as a single group, the Bi-Metric stem had a higher survival rate at 15 years than the reference group. The Cox regression analysis revealed that all cementless stems studied had a statistically significantly reduced risk of revision during the first 7 years after the primary operation when compared to the reference group ([Table 4](#T4){ref-type="table"}). Beyond 7 years of follow-up, the Bi-Metric and the ABG I stems still showed significantly lower revision risks than the cemented reference group ([Table 4](#T4){ref-type="table"}, [Figure 1A](#F1){ref-type="fig"}).

![Cox-adjusted survival curves for 19,859 stems and 19,859 cups in patients aged 55 years or older with stem designs (panel A) or cup designs (panel B) as the strata factors. The endpoint was defined as stem (A) or cup (B) revision due to aseptic loosening. Adjustment was made for age and sex. For an explanation of abbreviations, see [Table 4](#T4){ref-type="table"}.](ORT-1745-3674-81-042-g001){#F1}

###### 

Survival of cementless stems and the cemented reference group. Endpoint was defined as revision due to aseptic loosening of the stem. 7-, 10-, and 15-year survival rates were obtained from the Kaplan-Meier analysis. For prosthesis types, see [Table 1](#T1){ref-type="table"}

  A                  B                C        D      E       F               G       H             I       J             K                   L
  ------------------ ---------------- -------- ------ ------- --------------- ------- ------------- ------- ------------- ------------------- ----------
  All (≥ 55 years)                                                                                                                            
                     Anatomic Mesh    604      11.1   532     98 (97--99)     444     96 (94--98)   91      92 (89--95)   0.53 (0.37--0.76)   0.001
                      FU ≤ 7 years                                                                                        0.38 (0.21--0.71)   0.002
                      FU \> 7 years                                                                                       0.64 (0.40--1.00)   0.05
                     PCA Std          508      11.6   430     98 (96--99)     351     95 (92--97)   146     89 (86--93)   0.62 (0.44--0.88)   0.007
                      FU ≤ 7 years                                                                                        0.49 (0.27--0.89)   0.02
                      FU \> 7 years                                                                                       0.68 (0.44--1.05)   0.08
                     Bi-Metric        5,379    6.8    2,698   99 (99--99)     1,463   99 (98--99)   154     96 (94--98)   0.20 (0.15--0.27)   \< 0.001
                      FU ≤ 7 years                                                                                        0.18 (0.12--0.26)   \< 0.001
                      FU \> 7 years                                                                                       0.24 (0.16--0.37)   \< 0.001
                     ABG I            2,330    6.7    1,152   100 (99--100)   342     98 (97--99)   0       --            0.15 (0.09--0.25)   \< 0.001
                      FU ≤ 7 years                                                                                        0.08 (0.04--0.18)   \< 0.001
                      FU \> 7 years                                                                                       0.40 (0.20--0.80)   0.009
                     ABG II           1,489    2.5    0       --              0       --            0       --            0.31(0.13--0.76)    0.01
                      FU ≤ 7 years                                                                                        0.31 (0.13--0.76)   0.01
                      FU \> 7 years                                                                                       --                  --
                     Cemented         9,549    8.8    6,231   97 (96--97)     4,442   95 (94--95)   1,115   91 (90--92)   1.0 (reference)     --
                      FU ≤ 7 years                                                                                        1.0 (reference)     --
                      FU \> 7 years                                                                                       1.0 (reference)     --
                     Total            19,859                                                                                                  

For the age groups 55--64 years and 65--74 years, the Bi-Metric stem had a higher 15-year survival rate than the reference group (95% (CI: 92--97) vs. 84% (CI: 80--87) and 98% (CI: 97--99) vs. 90% (CI: 89--91), respectively).

Survival of cups -- aseptic loosening {#ss7}
-------------------------------------

When all patients aged 55 years or more were analyzed as a single group, the survival of the PCA Pegged cup at 15 years was lower than that of the reference group. Apart from this exception, there were no differences in survival rates between cementless cups and that of the reference group at 15-years. The Cox regression analysis revealed that the PCA Pegged cup had a significantly increased risk of revision both during the first 7 years postoperatively and beyond 7 years of follow-up. Furthermore, during the first 7 years the Press-Fit Universal, the Mallory, the Vision, and the ABG II cups had significantly reduced risks of revision compared to the reference group ([Table 5](#T5){ref-type="table"}). Beyond 7 years of follow-up, however, the lower revision risk remained only for the Press-Fit Universal cup ([Table 5](#T5){ref-type="table"}, [Figure 1B](#F1){ref-type="fig"}). The number of Vision and ABG II cups for analysis beyond 7 years was low ([Table 5](#T5){ref-type="table"}).

###### 

Survival of cementless cups and the cemented reference group. Endpoint was defined as revision due to aseptic loosening of the cup. 7-, 10-, and 15-year survival rates were obtained from the Kaplan-Meier analysis. For abbreviations, see [Table 4](#T4){ref-type="table"}

  A                  B                C        D      E       F              G       H             I       J             K                   L
  ------------------ ---------------- -------- ------ ------- -------------- ------- ------------- ------- ------------- ------------------- ----------
  All (≥ 55 years)                                                                                                                           
                     HG-II            604      11.1   531     99 (98--100)   445     97 (95--98)   92      88 (84--92)   0.75 (0.53--1.05)   0.09
                      FU ≤ 7 years                                                                                       0.50 (0.24--1.03)   0.0
                      FU \> 7 years                                                                                      0.82 (0.56--1.22)   0.3
                     PCA Pegged       508      11.6   432     94 (92--96)    353     86 (83--89)   148     75 (70--80)   1.91 (1.49--2.44)   \< 0.001
                      FU ≤ 7 years                                                                                       2.21 (1.44--3.38)   \< 0.001
                      FU \> 7 years                                                                                      1.70 (1.26--2.30)   \< 0.001
                     PFU              2,687    8.8    2,035   98 (97--99)    1,192   97 (96--98)   145     91 (87--94)   0.54 (0.42--0.70)   \< 0.001
                      FU ≤ 7 years                                                                                       0.68 (0.47--0.99)   0.04
                      FU \> 7 years                                                                                      0.45 (0.32--0.64)   \< 0.001
                     Mallory          637      8.8    517     99 (98--100)   275     96 (94--98)   10      --            0.52 (0.31--0.86)   0.01
                      FU ≤ 7 years                                                                                       0.35 (0.14--0.85)   0.02
                      FU \> 7 years                                                                                      0.68 (0.37--1.26)   0.2
                     Vision           2,055    3.4    152     99 (98--100)   0       --            0       --            0.49 (0.27--0.89)   0.019
                      FU ≤ 7 years                                                                                       0.51 (0.27--0.97)   0.04
                      FU \> 7 years                                                                                      3.39 (0.47--24.8)   0.2
                     ABG I            565      9.1    454     98 (96--99)    330     93 (90--95)   0       --            1.17 (0.83--1.66)   0.4
                      FU ≤ 7 years                                                                                       0.81 (0.43--1.52)   0.5
                      FU \> 7 years                                                                                      1.46 (0.96--2.24)   0.08
                     ABG II           3,254    4.3    700     99 (99--100)   14      --            0       --            0.20 (0.11--0.38)   \< 0.001
                      FU ≤ 7 years                                                                                       0.22 (0.11--0.43)   \< 0.001
                      FU \> 7 years                                                                                      0.19 (0.03--1.37)   0.1
                     Cemented         9,549    8.8    6,221   98 (98--98)    4,441   96 (96--97)   1,113   92 (91--93)   1.0 (reference)     --
                      FU ≤ 7 years                                                                                       1.0 (reference)     --
                      FU \> 7 years                                                                                      1.0 (reference)     --
                     Total            19,859                                                                                                 

For patients aged 55--64 years, the HG-II cup (87% (CI: 82--91)) and the PFU cup (88% (CI: 84--93)) had similar survival rates at 15 years as the reference cups (85% (CI 81-88)). For patients aged 65--74 years, the PFU cup had higher survival rate at 15 years than the reference group (96% (CI: 94--98) vs. 92% (CI: 91--93)\].

Survival of total hip replacements (cup + stem combinations) -- aseptic loosening {#ss8}
---------------------------------------------------------------------------------

When all patients aged 55 years or more were analyzed as a single group, the 15-year survival of the PCA Standard/PCA Pegged was lower than that of the reference group. The Cox regression analysis revealed that the PCA Standard/PCA Pegged had a significantly increased risk of revision beyond 7 years of follow-up. In contrast, all other cementless cup designs showed lower risk of revision than the cemented reference group during the first 7 years, and the Bi-Metric/Press-Fit Universal, the Bi-Metric/Mallory, and the ABG I/ABGII even beyond 7 years ([Figure 2A](#F2){ref-type="fig"}, [Table 6](#T6){ref-type="table"}). Beyond 7 years, the number of Bi-Metric/Vision THRs was low ([Table 6](#T6){ref-type="table"}).

![Cox-adjusted survival curves for 19,859 total hip replacements in patients aged 55 years or older with total hip replacement design as the strata factor. The endpoint was defined as revision of the stem and/or the cup due to aseptic loosening (panel A) or as revision for any reason (B). Adjustment was made for age and sex. For an explanation of abbreviations, see [Table 4](#T4){ref-type="table"}.](ORT-1745-3674-81-042-g002){#F2}

###### 

Survival of cementless total hip replacements and the cemented reference group. Endpoint was defined as revision due to aseptic loosening of the cup and/or the stem. 7-, 10-, and 15-year survival rates were obtained from the Kaplan-Meier analysis. For abbreviations, see [Table 4](#T4){ref-type="table"}

  A                 B                     C        D      E       F              G       H             I       J             K                   L
  ----------------- --------------------- -------- ------ ------- -------------- ------- ------------- ------- ------------- ------------------- ----------
  All ≥ 55 years)                                                                                                                                
                    Anatomic Mesh/HG-II   604      11.1   532     97 (96--98)    445     94 (92--96)   92      85 (80--89)   0.68 (0.51--0.90)   0.006
                     FU ≤ 7 years                                                                                            0.52 (0.32--0.86)   0.01
                     FU \> 7 years                                                                                           0.75 (0.53--1.06)   0.1
                    PCA Std/PCA Pegged    508      11.6   433     92 (90--95)    354     83 (80--87)   148     71 (66--76)   1.48 (1.19--1.83)   \< 0.001
                     FU ≤ 7 years                                                                                            1.37 (0.96--1.96)   0.09
                     FU \> 7 years                                                                                           1.46 (1.11--1.92)   0.006
                    Bi-Metric/PFU         2,687    8.8    2,035   98 (97--98)    1,192   96 (96--97)   145     90 (87--93)   0.37 (0.29--0.46)   \< 0.001
                     FU ≤ 7 years                                                                                            0.39 (0.29--0.54)   \< 0.001
                     FU \> 7 years                                                                                           0.34 (0.25--0.47)   \< 0.001
                    Bi-Metric/Mallory     637      8.8    517     99 (98--100)   275     96 (94--98)   10      --            0.36 (0.23--0.58)   \< 0.001
                     FU ≤ 7 years                                                                                            0.27 (0.13--0.55)   \< 0.001
                     FU \> 7 years                                                                                           0.48 (0.26--0.88)   0.02
                    Bi-Metric/Vision      2,055    3.4    152     99 (98--99)    0       --            0       --            0.37 (0.23--0.60)   \< 0.001
                     FU ≤ 7 years                                                                                            0.37 (0.23--0.62)   \< 0.001
                     FU \> 7 years                                                                                           2.53 (0.35--18.4)   0.4
                    ABG I/ABG I           565      9.1    455     97 (96--99)    330     92 (90--95)   0       --            0.75 (0.54--1.04)   0.09
                     FU ≤ 7 years                                                                                            0.51 (0.29--0.87)   0.01
                     FU \> 7 years                                                                                           1.03 (0.68--1.55)   0.9
                    ABG I/ABG II          1,765    5.9    700     99 (99--100)   14      --            0       --            0.12 (0.06--0.22)   \< 0.001
                     FU ≤ 7 years                                                                                            0.12 (0.06--0.24)   \< 0.001
                     FU \> 7 years                                                                                           0.13 (0.02--0.93)   0.04
                    ABG II/ABG II         1,489    2.5    0       --             0       --            0       --            0.33 (0.15--0.74)   0.007
                     FU ≤ 7 years                                                                                            0.34 (0.15--0.76)   0.009
                     FU \> 7 years                                                                                           --                  --
                    Cemented              9,549    8.8    6,234   96 (96--96)    4,447   93 (93--94)   1,116   88 (87--89)   1.0 (reference)     --
                     FU ≤ 7 years                                                                                            1.0 (reference)     --
                     FU \> 7 years                                                                                           1.0 (reference)     --
                    Total                 19,859                                                                                                 

For patients aged 55--64 years, the 15-year survival rate of the Bi-Metric/Press-Fit Universal was higher than that for the reference group (88% (CI: 84--92) vs. 78% (CI: 74--82)). For patients aged 65--74 years also, the survival rate at 15 years of the Bi-Metric/Press-Fit Universal (95% (CI: 93--98)) was higher than that for the reference group (87% (CI: 86--89%)).

Survival of total hip replacements (cup + stem combinations) -- all revisions {#ss9}
-----------------------------------------------------------------------------

When all patients aged 55 years or more were analyzed as a single group, the survival rate at 15 years of the cementless designs was lower than that for the reference group. The Cox regression analysis revealed that during the first 7 years postoperatively, the ABG I/ABGII had a significantly reduced risk of revision compared to the cemented reference group ([Table 7](#T7){ref-type="table"}). Furthermore, the ABG II/ABG II combination was the only design to show an increased risk of revision during the first 7 years after the primary operation ([Table 7](#T7){ref-type="table"}). Beyond 7 years of follow-up, however, several cementless designs (the Anatomic Mesh/HG-II, the PCA Standard/PCA Pegged, and the ABG I/ABG I) showed higher risk of revision than the cemented reference group ([Table 7](#T7){ref-type="table"}, [Figure 2B](#F2){ref-type="fig"}), and none of the cementless designs had a lower risk of revision than the reference group beyond 7 years. Beyond 7 years, the number of ABG I/ABG II THRs was low ([Table 7](#T7){ref-type="table"}).During the first 7 years postoperatively in the patients aged 55--64 years, the risk ratio for revision of cementless THRs for any reason was not significantly different from that of the cemented reference group ([Table 7](#T7){ref-type="table"}). Beyond 7 years of follow-up, however, the revision risk of the Anatomic Mesh/HG-II (RR = 1.6, CI: 1.2--2.2), the PCA Std/PCA Pegged (RR = 1.5, CI: 1.1--2.1), the Bi-Metric/PFU (RR = 1.5, CI: 1.1--1.9), the Bi-Metric/Mallory (RR = 2.0, CI: 1.3--3.1), and the ABG I/ABG I (RR = 3.2, CI: 2.3--4.6) was higher than that of the reference group.

###### 

Survival of cementless total hip replacements and the cemented reference group. Endpoint was defined as revision of the cup and/or the stem for any reason. 7-, 10-, and 15-year survival rates were obtained from the Kaplan-Meier analysis. For an explanation of abbreviations, see [Table 4](#T4){ref-type="table"}

  A                  B                     C        D      E       F                G                 H                I             J                   K                   L
  ------------------ --------------------- -------- ------ ------- ---------------- ----------------- ---------------- ------------- ------------------- ------------------- ----------
  55--64                                                                                                                                                                     
                     Anatomic Mesh/HG-II   385      11.2   343     94 (92--97)      296               89 (86--92)      57            70 (64--76)         1.18 (0.91--1.54)   0.2
                     PCA Std/PCA Pegged    347      12.2   303     91 (88--94)      262               82 (78--86)      119           66 (61--72)         1.32 (1.03--1.69)   0.03
                     Bi-Metric/PFU         1,863    9.1    1,488   93 (92--94)      872               86 (85--88)      102           66 (61--72)         1.18 (0.97--1.44)   0.09
                     Bi-Metric/Mallory     266      9.0    224     95 (92--97)      119               83 (77--88)      8             72 (61--82)         1.27 (0.90--1.80)   0.2
                     Bi-Metric/Vision      1,080    3.8    96      95 (93--97)      0                 --               0             --                  1.05 (0.72--1.54)   0.8
                     ABG I/ABG I           280      9.4    239     90 (87--94)      174               74 (69--80)      0             --                  2.13 (1.62--2.81)   \< 0.001
                     ABG I/ABG II          746      6.0    309     95 (93--97)      6                 --               0             --                  0.90 (0.62--1.31)   0.6
                     ABG II/ABG II         610      2.4    0       --               0                 --               0             --                  1.54 (0.93--2.53)   0.0
                     Cemented              1,204    9.5    837     92 (91--94)      616               89 (87--91)      210           76 (72--79)         1.0 (reference)     --
                     Subtotal              6,781                                                                                                                             
  65--74                                                                                                                                                                     
                     Anatomic Mesh/HG-II   186      11.3   165     94 (90--97)      133               90 (86--95)      34            77 (67--87)         1.05 (0.70--1.56)   0.8
                     PCA Std/PCA Pegged    133      11.0   112     91 (86--96)      85                81 (74--88)      30            70 (61--80)         1.78 (1.23--2.58)   0.002
                     Bi-Metric/PFU         740      8.5    525     94 (92--96)      320               90 (87--93)      45            85 (81--89)         0.89 (0.68--1.16)   0.4
                     Bi-Metric/Mallory     274      8.8    223     95 (92--98)      119               91 (87--95)      2             --                  0.88 (0.57--1.34)   0.5
                     Bi-Metric/Vision      850      3.1    51      94 (90--97)      0                 --               0             --                  1.10 (0.74--1.63)   0.6
                     ABG I/ABG I           238      9.0    187     91 (87--95)      142               86 (81--91)      0             --                  1.34 (0.93--1.92)   0.1
                     ABG I/ABG II          789      5.9    311     98 (96--99)      8                 --               0             --                  0.48 (0.31--0.75)   0.001
                     ABG II/ABG II         647      2.4    0       --               0                 --               0             --                  1.62 (1.05--2.51)   0.03
                     Cemented              4,964    9.3    3,446   94 (93--95)      2,635             90 (89--91)      722           85 (83--87)         1.0 (reference)     --
                     Subtotal 8,821                                                                                                                                          
  \>75                                                                                                                                                                       
                     Anatomic Mesh/HG-II   33       8.9    25      90 (80--100)     17                --               2             --                  1.69 (0.54--5.32)   0.4
                     PCA Std/PCA Pegged    28       7.6    18      --               8                 --               1             --                  2.44 (0.78--7.66)   0.1
                     Bi-Metric/PFU         84       5.6    31      93 (86--99)      14                --               1             --                  1.60 (0.65--3.90)   0.3
                     Bi-Metric/Mallory     97       8.1    73      98 (95--100)     39                1                --                                0.45 (0.11--1.80)   0.3
                     Bi-Metric/Vision      125      2.8    6       --               0                 --               0             --                  2.09 (0.92--4.77)   0.08
                     ABG I/ABG I           47       8.0    33      100 (100--100)   21                100 (100--100)   0             --                  --                  --
                     ABG I/ABG II          230      5.6    82      97 (94--99)      1                 --               0             --                  0.70 (0.31--1.60)   0.4
                     ABG II/ABG II         232      2.6    0       --               0                 --               0             --                  1.69 (0.85--3.35)   0.1
                     Cemented              3,381    7.6    1,954   96 (95--97)      1,198             95 (94--96)      186           94 (92--95)         1.0 (reference)     --
                     Subtotal              4,257                                                                                                                             
  All (≥ 55 years)                                                                                                                                                           
                     Anatomic Mesh/HG-II   604      11.1   532     94 (92--96)      446               89 (87--92)      93            72 (67--78)         1.19 (0.97--1.47)   0.1
                      FU ≤ 7 years                                                                                                                       0.91 (0.64--1.29)   0.6
                      FU \> 7 years                                                                                                                      1.32 (1.01--1.72)   0.04
                     PCA Std/PCA Pegged    508      11.6   433     91 (89--94)      354 82 (79--86)   149              67 (62--72)   1.51 (1.24--1.83)   \< 0.001            
                      FU ≤ 7 years                                                                                                                       1.26 (0.91--1.75)   0.2
                      FU \> 7 years                                                                                                                      1.52 (1.18--1.95)   0.001
                     Bi-Metric/PFU         2,687    8.8    2,044   93 (92--94)      1,205             87 (86--89)      147           71 (67--75)         1.10 (0.95--1.27)   0.2
                      FU ≤ 7 years                                                                                                                       0.98 (0.80--1.20)   0.8
                      FU \> 7 years                                                                                                                      1.18 (0.96--1.46)   0.1
                     Bi-Metric/Mallory     637      8.8    519     95 (93--97)      277               89 (85--92)      10            --                  1.05 (0.81--1.36)   0.7
                      FU ≤ 7 years                                                                                                                       0.76 (0.52--1.12)   0.2
                      FU \> 7 years                                                                                                                      1.43 (1.00--2.05)   0.05
                     Bi-Metric/Vision      2,055    3.4    153     95 (93--96)      0                 --               0             --                  0.99 (0.76--1.29)   0.9
                      FU ≤ 7 years                                                                                                                       0.98 (0.75--1.29)   0.9
                      FU \> 7 years                                                                                                                      2.75 (0.38--19.9)   0.3
                     ABG I/ABG I           565      9.1    458     91 (89--94)      336               81 (77--84)      0              --                 1.74 (1.41--2.15)   \< 0.001
                      FU ≤ 7 years                                                                                                                       1.27 (0.92--1.74)   0.1
                      FU \> 7 years                                                                                                                      2.30 (1.73--3.06)   \< 0.001
                     ABG I/ABG II          1,765    5.9    701     96 (95--97)      14                --               0             --                  0.66 (0.51--0.86)   0.002
                      FU ≤ 7 years                                                                                                                       0.63 (0.48--0.84)   0.001
                      FU \> 7 years                                                                                                                      0.69 (0.28--1.69)   0.4
                     ABG II/ABG II         1,489    2.5    0        --              0                 --               0             --                  1.52 (1.13--2.05)   0.006
                      FU ≤ 7 years                                                                                                                       1.46 (1.08--1.97)   0.01
                      FU \> 7 years                                                                                                                      --                  --
                     Cemented              9,549    8.8    6,237   94 (94--95)      4,449             91 (91--92)      1,117         86 (84--87)         1.0 (reference)     --
                      FU ≤ 7 years                                                                                                                       1.0 (reference)      --
                      FU \> 7 years                                                                                                                      1.0 (reference)     --
                     Total                 19,859                                                                                                                            

During the first 7 years in the patients aged 65--74 years, the risk ratio for revision due of cementless THRs for any reason was not significantly different from that of the cemented reference group, except that the ABG I/ABG II had a reduced risk of revision compared to that of the reference group (RR = 0.45, CI: 0.28--0.72). Beyond 7 years of follow-up, the risk ratio for revision due of cementless THRs for any reason was not significantly different from that of the cemented reference group, except that the PCA Std/PCA Pegged (RR = 2.0, CI: 1.3--3.3) had an increased risk of revision compared to the reference group.

Discussion {#ss10}
==========

We found that the survival rate for aseptic loosening of the best performing cementless stems in patients aged 55--74 years was higher than that of the cemented reference stems. Biological fixation in itself seems to be a reliable method in THA of elderly patients. However, the survival rate of the cemented reference implants for any reason was higher than that of cementless implants. Polyethylene wear and osteolysis remain a serious problem with all cementless cup designs with unplugged screw-holes and poor liners. A longer follow-up is required in order to determine whether cups with plugged screw-holes and modern liner options provide any solution to the wear-problem.

Registry-based studies have certain limitations. The coverage of the Finnish Arthroplasty Register before the period 1994--1995 was only 90% ([@CIT0037]). The missing 10% of implant data may have caused bias in our study. It is also possible that only a few centers performed most of the implantations of certain designs. However, a single center with poor results would be unlikely to have a major effect on the results in a study with such a high number of implants. Moreover, it is the purpose of registry studies to evaluate population-based results, including hospitals of variable standards. Another possible limitation of registry-based studies is their single definition of failure, i.e. a revision operation. There may be patients with osteolysis or loosened implants who are too ill to undergo revision surgery or who simply prefer not to do so. Furthermore, the adjustments in the Cox model in our study were performed only for 2 confounders: age and sex. Many other potential confounders, such as antibiotic prophylaxis or hospital operative volume, may be associated with the relationship between implant brand and revision rate.

The implant designs varied over the long study period ([Table 1](#T1){ref-type="table"}). Some of the 3 cemented designs we used as the reference group were implanted over the whole study period, starting in 1980. Any recent developments in cementing techniques that were adopted may have resulted in higher long-term survival rates for those prostheses that were implanted later in the study period ([@CIT0018], [@CIT0024]). However, the cemented implants we chose were the best performing designs in the Finnish Register regardless of the time period they were implanted ([@CIT0030]).

The proportional hazards assumption of the Cox model (meaning that the relative difference between revision rates should be constant over time since the primary operation) was not reached in some analyses. Thus, adjusted risk ratios were also established within time intervals (0--7 years and \> 7 years after the primary operation). Follow-up beyond 7 years revealed that the results of cementless cups, and therefore of cementless THRs, detoriate with time.

The revision rates that we found for cementless implants were similar to previous findings ([@CIT0023], [@CIT0041], [@CIT0043], [@CIT0002], [@CIT0038], [@CIT0014], [@CIT0005], [@CIT0020], [@CIT0010], [@CIT0019], [@CIT0025], [@CIT0028], [@CIT0032], [@CIT0021], [@CIT0011], [@CIT0008], [@CIT0012], [@CIT0040]).

We found a higher long-term survival rate for the Bi-Metric stem than for the reference stems in patients aged 55--74 years. When revisions for aseptic loosening were analyzed, the Press-Fit Universal cup was found to have a long-term survival rate similar to those of the reference cups in patients aged 55--74 years. In Finland, Biomet cups were used with Hexloc liners until 1995, and with Ringloc liners after that. In an earlier study based on data from the Finnish Register, survivorship of the Press-Fit Universal cups with Hexloc liners was poor ([@CIT0036]). Reasons for increased wear of Hexloc liners were thin polyethylene, poor quality of the polyethylene, cylindrical design, and a poor locking mechanism ([@CIT0036], [@CIT0038]). Furthermore, the screw-holes of Press-Fit Universal cups were unplugged. In the present study, the survival rate of the Bi-Metric/Press-Fit Universal at 15 years was lower than that of the cemented reference group when all revisions were taken into account. However, the adjusted risk of revision of the Bi-Metric/Press-Fit Universal for any reason was similar to that of the reference group. This finding is probably influenced by the positive effect of Ringloc liners (starting in 1995) on the results with the Bi-Metric/Press-Fit Universal. Unfortunately, it is not possible to analyze the survival rate of the Press-Fit Universal cups with Hexloc liners and with Ringloc liners separately in the Finnish Register data. Revision risk for any reason with the Bi-Metric/Vision was similar to that for the cemented reference group ([Table 7](#T7){ref-type="table"}, [Figure 2B](#F2){ref-type="fig"}). However, survival rates at 10-years for the Vision cup with Ringloc-liners and plugged screw-holes are not yet available.

The survival rate for aseptic loosening of the Anatomic Mesh/Harris-Galante II at 15 years was not significantly different from that of the cemented reference group. Nonetheless, the survival rate of the Anatomic Mesh/HG-II for any reason at 15 years was poor. Again, this finding can be attributed to wear-related factors. The Anatomic Mesh/Harris-Galante II is no longer being implanted in patients in Finland.

The 15-year survival rate for the PCA Standard stem in our study was lower than those for the best-performing stems. The PCA Standard/PCA Pegged prosthesis is no longer being implanted in patients in Finland.

The 10-year survival rate of the ABG I/ABG I for any reason was lower than that for the reference group. However, the survival rate of the ABG I stem at 10 years for aseptic loosening was higher than that for the reference group. For this reason, and because of poor liners in the ABG I cup design, in Finland the ABG I stem has been widely used along with the ABG II cup with plugged screw-holes and thicker Duration liners consisting of stabilized polyethylene (Stryker, Mahwah, NJ). In our study, the risk of revision of the ABG I/ABG II for any reason in patients aged 65--74 was lower than that for the reference group when all revisions were taken into account ([Table 7](#T7){ref-type="table"}, [Figure 2B](#F2){ref-type="fig"}). However, the survival rates for the ABG I/ABG II at 10 years are not yet available. Survivorship of modular cementless cups may dramatically worsen after 7--10 years of follow-up due to excessive wear and osteolysis, as indicated by the beyond-7-years survival analysis in our study. Thus, it is too early to draw any definite conclusions about the long-term success of this hip implant.

The ABG II stem differs from the ABG I stem regarding its titanium alloy composition, its stem geometry, its macrotexture, its conus size, and the option with Zirkonia heads (ABG II Cement-Free Hip System). The risk of revision of the ABG II/ABG II for any reason was higher than that for the reference group. The mean follow-up time for the ABG II/ABG II was short: only 2.5 years ([Table 1](#T1){ref-type="table"}). The proportion of periprothetic fractures for all revisions of the ABG II/ABG II was high: 37% ([Table 3](#T3){ref-type="table"}). This finding is in accordance with clinical experience in Finland. The ABG II stem appears to be vulnerable to perioperative periprothetic femoral fractures, due to its anatomical and conical shape. There were only 3 aseptic loosenings of the ABG II stem during the study period ([Table 3](#T3){ref-type="table"}). The problem with an early aseptic loosening of a cementless stem is that there may not have been any osseointegration at all from the beginning, due to undersizing or some other technical failure. Thus, strictly speaking any associated loosening could not have happened either. A longer follow-up time is needed to determine whether either the ABG I/ABG II or the ABG II/ABG II provides a long-term solution to the wear problem. Only a few Zirkonia head or liner fractures have been reported in Finland ([Table 3](#T3){ref-type="table"}).

For patients aged 75 years and older, the survival rates were similar between cementless implants and the cemented reference group, except that the PCA Pegged cup had an increased risk of revision compared to the cemented reference group. This is in accordance with the results of a previous report from the Finnish Arthroplasty Register ([@CIT0029]). However, there was little information for this subgroup.

In conclusion, cementless, proximal porous-coated stems are a good option for elderly patients. Polyethylene wear and osteolysis remain a problem for cementless designs with unplugged screw-holes and low-quality liners.
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